《嘉德诺Cardinal Health（CAH）2023财年年度报告（英文版）（104页）.pdf》由会员分享，可在线阅读，更多相关《嘉德诺Cardinal Health（CAH）2023财年年度报告（英文版）（104页）.pdf（104页珍藏版）》请在三个皮匠报告上搜索。

1、CardinalHealth lfi,A r,art,rJr a a A I I rr g 11/I a ir II gI I ti5 Y I,g gA I I Jr A r,a I,5 Y ,a u a rr I u a4 ,OfY aX P 11 a I I v a I,/l f 1 xlaauA t:IJason HollarChief Executive Officer Consistent with what you heard at our June 2023 Investor Day,these results were achieved through our teams co

2、mmitment to prioritize the core of our business and to better serve our customers so they,in turn,can focus on caring for their patients.Cardinal Health is a crucial link between these clinical and operational sides of healthcare,delivering end-to-end solutions our customers rely on each day,and we

3、are intent on moving healthcare forward.Today,as a result of our actions and work in fscal 2023,we are operating as a more focused and more resilient company.We are proud of the fact that in fscal 2023,we:Our management team and Board of Directors,with support from the Business Review Committee,cont

4、inue to work through the comprehensive review of the companys strategy,portfolio,capital allocation framework and operations.Given the importance of the work in maximizing our potential for the beneft of all stakeholders,the Board has extended the term of the Business Review Committee for an additio

5、nal year.As I conclude my frst year as CEO,I am energized by the progress we achieved in fscal 2023 and optimistic about our year ahead.Delivered non-GAAP diluted earnings per share1 of$5.79,growth of 14%Generated both operating cash fow and non-GAAP adjusted free cash fow of$2.8 billionReturned mor

6、e than$2.5 billion to shareholders,through dividends and share repurchasesGrew Pharmaceutical Segment proft by13%to$2 billionAchieved sequential improvement in Medical Segment proft,with$82 millionin the fourth quarter,driven by progress on our Medical Improvement PlanDear shareholders,1 GAAP dilute